ASML
Another analyst, another ASML love note
RBC Capital decided ASML deserved a slightly bigger spotlight, bumping its price target to €1,700 from €1,625 while sticking with an Outperform rating. Not exactly a plot twist, but in analyst-land, that’s basically a fresh coat of paint on an already shiny car.
The bull case is still the same old song
The broader takeaway here isn’t just RBC’s call. Barclays also reiterated an Overweight rating, Jefferies stayed on Hold, and BofA kept its Buy view — which means Wall Street is still mostly treating ASML like the VIP bouncer at the chip-industry nightclub. If you want the newest AI and advanced chips, ASML’s EUV tools are still the ticket.
But nobody’s pretending the stock is cheap
There’s a catch: InvestingPro said the shares look overvalued versus fair value. So yes, the analysts are nodding approvingly, but they’re also doing that thing where they like the stock and still squint at the valuation. Classic Wall Street.
Why investors should care
ASML’s order intake and demand for its EUV systems remain the big storyline, and that’s what keeps the bullish ratings coming. Still, the stock doesn’t get to ignore pricing forever — if expectations are already sky-high, even a good quarter can feel like showing up to a party where everyone already ate the dessert.
Big picture: ASML still has the kind of business that makes analysts feel warm and fuzzy, but the valuation means the bar is set somewhere near the ceiling.